Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

18.98 +0.33 (+1.76%)
Streaming Delayed Price Updated: 9:52 AM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeu ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
3 Stocks That Have Generated 1,000% Returns in Just 2 Years
Should you add these fast-growing stocks to your portfolio? 
Via The Motley Fool
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
From Summit Therapeutics Inc.
Via Business Wire
Preview: Summit Therapeutics's Earnings
Via Benzinga
From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B). 
Via News Direct
Is Summit Therapeutics a Millionaire Maker?
The potential upside of this stock is undeniably meaty. 
Via The Motley Fool
(SMMT) - Analyzing Summit Therapeutics's Short Interest
Via Benzinga
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy. 
Via The Motley Fool
Billionaire Bob Duggan Snags $33M Miami Penthouse Amid Summit Therapeutics 689% Stock Rally
Duggan, an 80-year-old originally from California, was particularly impressed by the breathtaking views from the 57th floor. 
Via Benzinga
Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
From Summit Therapeutics Inc.
Via Business Wire
Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?
Millennium Management just initiated a position in a small biotech company developing a new cancer drug. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Up 700% This Year, Is It Too Late to Invest in This Stock?
The shares have experienced a pullback in the past couple of weeks. 
Via The Motley Fool
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
It's hard to go wrong with either company, but one is more appealing. 
Via The Motley Fool
3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
It's easier to invest confidently when you know both the pros and the cons in full. 
Via The Motley Fool
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
The investment bank analysts who follow these stocks think they can soar even further, with some caveats. 
Via The Motley Fool
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Eleven large-cap stocks were worst performers last week. Decline in Stars performance and sales, regulations and supply issues caused the drop. 
Via Benzinga
Is Summit Therapeutics a Millionaire Maker?
This company's promising cancer drug could challenge Merck's $25 billion crown jewel. 
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Could Summit Therapeutics Become the Next Merck?
Recent developments are forcing comparisons between these two drugmakers. 
Via The Motley Fool
Why Phoenix Motor Shares Are Trading Higher By 150%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
From Summit Therapeutics Inc.
Via Business Wire
Where Will Summit Therapeutics Be in 3 Years?
There's a lot riding on how its collaborator's studies end up performing. 
Via The Motley Fool
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar. 
Via Benzinga
Has Summit Therapeutics Stock Already Peaked?
Summit Therapeutics stock is up a remarkable 700% this year. 
Via The Motley Fool
Is Summit Therapeutics Stock a Buy?
Its alliance with a successful foreign biotech could be decisive for the stock. 
Via The Motley Fool
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio? 
Via Benzinga
2 High-Potential Growth Stocks You Shouldn't Overlook
These two growth stocks have plenty of room to run. 
Via The Motley Fool
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
One of them is performing much better than the other this year. 
Via The Motley Fool
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
These relatively small companies are developing new cancer therapies that could generate billions in annual sales. 
Via The Motley Fool
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.